Liraglutide

Obesity medications were prescribed to very few Military Health System beneficiaries between October 2017 and September 2022, according to a study published in Obesity.

Although glucagon-like peptide-1 receptor agonist use prior to upper endoscopy was linked to a higher rate of retained gastric contents, evidence supports prolonged fasting as the “optimal approach” rather than routine discontinuation.

PHILADELPHIA — Treatment with liraglutide appeared to reduce cognitive decline and slow volume loss in several areas of the brain after 1 year among individuals with mild to moderate Alzheimer’s dementia, according to new research.

There are many important factors primary care providers must consider when prescribing popular anti-obesity medications, according to experts.

Teva Pharmaceuticals launched the first generic GLP-1 receptor agonist, liraglutide 1.8 mg, for patients aged 10 years or older with type 2 diabetes.

Published results showed exercise in combination with glucagon-like peptide-1 receptor agonist treatment may be an effective weight loss strategy that preserves clinically relevant site-specific bone mineral density.

Teva Pharmaceuticals announced it has launched the first generic version of a GLP-1 receptor agonist in the United States, liraglutide 1.8 mg.

A “heat dome” like the one that descended over the Northeast and Midwest United States may increase cardiovascular risk, especially in vulnerable populations, according to Jonathan Newman, MD, MPH.

PHILADELPHIA — In the cardiovascular outcomes analysis of the GRADE trial, liraglutide was linked to lower risk for certain CV outcomes compared with other glucose-lowering therapies, researchers reported.

BOSTON — From 2019 to 2023, insurance covered GLP-1 receptor agonist prescriptions at a Texas hospital for less than 70% of young people with type 2 diabetes and less than 40% of those with obesity.